User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

3014

Interactions with Platform & by Email *

INTERACTIONS

543

Unique # Participated *

PARTICIPANTS

90

Responses Validated *

VALIDATIONS

26

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Outlook.....II-4
Current & Future Analysis.....II-4
Underdiagnosis – A Key Market Deterrent.....II-4
1$100
   Increasing Awareness- A Key to Success.....II-5
Reaching Out to Urologists – A Key Strategy.....II-5
Improved OAB Medications to Drive Growth.....II-5
1$100
   Ageing Population Reflect Significant market Opportunity.....II-6
Table 1: Ageing (65+) Demographics as % of Total Population by Country (2000, 2010, 2025) (includes corresponding Graph/Chart).....II-6
1$350
   Table 2: Prevalence (%) of Overactive Bladder Symptoms by Age (includes corresponding Graph/Chart).....II-7
Meager OAB Developmental Pipeline Deters Growth Prospects.....II-7
Generics Stalls Revenues.....II-7
1$350
   The Branded Drugs Landscape.....II-8
Table 3: Sales of Major Overactive Bladder Drugs (2009) (In US$ Million) (includes corresponding Graph/Chart).....II-8
1$350
   Review of Select Available Drugs.....II-9
Detrol and Detrol LA (Tolterodine tartrate).....II-9
VESIcare® (solifenacin succinate).....II-9
SANCTURA® (trospium chloride).....II-9
Toviaz® (fesoterodine fumarate).....II-9
Enablex® (Darifenacin).....II-9
Ditropan and Ditropan XL (Oxybutynin chloride).....II-9
1$100
   Oxytrol (Oxybutynin Patch).....II-10
The OAB Brand Matrix.....II-10
1$100
   How Does Normal Urinary Bladder Function?.....II-11
What is Urinary Incontinence?.....II-11
Male Incontinence.....II-11
1$100
   Women More Prone to Incontinency than Men.....II-12
Incontinence Among Children.....II-12
Types of Urinary Incontinence.....II-12
Stress Incontinence.....II-12
1$100
   Urge Incontinence.....II-13
Functional Incontinence.....II-13
Overflow Incontinence.....II-13
1$100
   Mixed Incontinence.....II-14
Reflex Incontinence.....II-14
Transient Incontinence.....II-14
Traumatic Incontinence.....II-14
1$100
   Definition.....II-15
Types.....II-15
By Incontinence.....II-15
Overactive Bladder Dry.....II-15
Overactive Bladder Wet.....II-15
By Symptomatic Causes.....II-15
Neurogenic OAB.....II-15
1$100
   Idiopathic OAB.....II-16
Etiology.....II-16
Symptoms.....II-16
Impact of Overactive Bladder on Quality of Life.....II-16
1$100
   Diagnosis.....II-17
Measurement of Postvoid Residual Urine.....II-17
Cystoscopy.....II-17
Uroflowmetry.....II-17
Cystometry.....II-17
1$100
   Electromyography.....II-18
Video Urodynamics.....II-18
Treatment Options.....II-18
Behavioral Remedies.....II-18
Pharmacotherapy.....II-18
Anticholinergic agents.....II-18
1$100
   Other Therapeutic Approaches.....II-19
Device Therapy.....II-19
Device Therapies in Men.....II-19
Device and Minimally-Invasive Therapies in Women.....II-19
Neuromodulation.....II-19
Vaginal Devices.....II-19
1$100
   Collagen Injections.....II-20
Retropubic Suspension.....II-20
Sling Procedure.....II-20
Midurethral Slings.....II-20
Dietary Changes and Alternative Medicines.....II-20
1$100
   Dr. Reddy’s Laboratories Launches Bispec.....II-21
Watson Pharmaceuticals Introduces GELNIQUE™ (oxybutynin chloride) Gel 10%.....II-21
Pfizer Launches TOVIAZ®.....II-21
1$100
   Warner Chilcott Purchases US Rights of Enablex from Novartis.....II-22
Serenity Pharmaceuticals and Allergan Enter Into Agreement.....II-22
Astellas Pharma Applies for Approval of YM178 in Japan.....II-22
Kyorin Pharmaceutical and Ono Pharmaceutical Independently File NDA.....II-22
1$100
   Endo Pharmaceuticals Purchases Indevus Pharmaceuticals.....II-23
Allergan Signs Co-promotion Agreement with Quintiles Transnational.....II-23
P&G Inks Agreement with Warner Chilcott.....II-23
1$100
   Astellas Pharma to Introduce Vesicare in China.....II-24
Kyorin Pharmaceutical Inks Licensing Agreement with Eisai.....II-24
Astellas Pharma Unveils Expansion Plans in India.....II-24
Speciality European Pharma Obtains Distribution Rights to Regurin and Regurin
  XL.....II-24
1$100
   Toray and Taiho Pharmaceutical Enter into Alliance.....II-25
Astellas Pharma Files Patent Infringement Lawsuit against Teva Pharmaceutical.....II-25
Indevus Pharmaceuticals Inks License Agreement with Allergan.....II-25
1$100
   Asahi Kasei Obtains Intellectual Property Rights of Flivas from Roche
  Diagnostics.....II-26
1$100
   Allergan, Inc. (US).....II-27
Antares Pharma, Inc. (US).....II-27
Apogepha Arzneimittel GmbH (Germany).....II-27
1$100
   Astellas Pharma, Inc. (Japan).....II-28
Auxilium Pharmaceuticals, Inc. (US).....II-28
Kissei Pharmaceuticals Co., Ltd. (Japan).....II-28
KYORIN Pharmaceutical Co., Ltd. (Japan).....II-28
1$100
   Novartis AG (Switzerland).....II-29
Ono Pharmaceutical Co., Ltd. (Japan).....II-29
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (USA).....II-29
1$100
   Pfizer, Inc. (US).....II-30
SALVAT Biotech (Spain).....II-30
Sepracor Pharmaceuticals, Inc. (Canada).....II-30
Watson Pharmaceuticals, Inc. (US).....II-30
2$200
   Table 4: World Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics by Country/Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-321$350
   Table 5: World Historic Review for Overactive Bladder Therapeutics by Country/Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Consumption in Thousand Metric Tons for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-331$350
   Table 6: World 15-Year Perspective for Overactive Bladder Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-341$350
   A. Market Analysis.....II-35
Overview.....II-35
Competition.....II-35
Table 7: US Market for Overactive Bladder Therapeutics (2009): Percentage Share Breakdown by Drugs - Detrol/Detrol LA, Vesicare, Enablex, Generic Oxybutynin, Sanctura/Sanctura XR and Others (includes corresponding Graph/Chart).....II-35
1$350
   Table 8: US Market for OAB Drugs: Prescription Share for Oral and Transdermal Medications (includes corresponding Graph/Chart).....II-36
Patent Expiry of Select Overactive Bladder Drugs.....II-36
Strategic Corporate Developments.....II-36
2$350
   Key Player Review.....II-382$125
   B. Market Analytics.....II-40
Table 9: The United States Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-40
1$350
   Table 10: The United States Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-411$350
   A. Market Analysis.....II-42
Strategic Corporate Developments.....II-42
Key Player Review.....II-42
2$125
   B. Market Analytics.....II-44
Table 11: Japanese Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-44
1$350
   Table 12: Japanese Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-451$350
   A. Market Analysis.....II-46
Key Player Review.....II-46
1$100
   B. Market Analytics.....II-47
Table 13: European Past, Current & Future Market Analysis for Overactive Bladder Therapeutics by Country/Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-47
1$350
   Table 14: European Historic Review for Overactive Bladder Therapeutics by Country/Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-481$350
   Table 15: European 15-Year Perspective for Overactive Bladder Therapeutics by Country/ Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-491$350
   Market Analysis.....II-50
Table 16: French Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-50
1$350
   Table 17: French Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-511$350
   Market Analysis.....II-52
Table 18: German Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-52
1$350
   Table 19: German Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-531$350
   Market Analysis.....II-54
Table 20: Italian Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-54
1$350
   Table 21: Italian Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-551$350
   Market Analysis.....II-56
Table 22: The UK Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-56
1$350
   Table 23: The UK Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-571$350
   Market Analysis.....II-58
Table 24: Rest of Europe Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-58
1$350
   Table 25: Rest of Europe Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-591$350
   A. Market Analysis.....II-60
Strategic Corporate Developments.....II-60
1$100
   B. Market Analytics.....II-61
Table 26: Rest of World Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart).....II-61
1$350
   Table 27: Rest of World Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-621$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com